Moreover, PDK1 inhibitor JX06 rendered cancer cells more sensitive to gefitinib treatment <i>in vivo</i>, and JX06 and gefitinib combination treatments have a synergic effect to inhibit tumor growth. This evidence concerns the gene PDK1 and cancer.